Hong Kong Baomingtang International Group Co., Ltd. was founded in the eighth year of Xianfeng, 1858 AD, with a history of over 100 years. The company's headquarters is located in Shenzhen, China. Shenzhen Baomingtang Health Products Co., Ltd. was established in June 1998. At present, more than 100 branches and specialty stores have been established in major and medium-sized cities across China, including Beijing, Shanghai, East China, South China, and Guangdong;

Shenzhen Tianneng Pharmaceutical Co., Ltd. is located in the Tianneng Science and Technology Park in Pingdi Street, Longgang District, Shenzhen, with beautiful scenery, pleasant climate, lush trees, and convenient transportation; Having a spacious, bright, and tidy garden style factory, covering an area of 12000 square meters, including a building area of 17000 square meters, the environment is beautiful, and it is a teaching, research, and internship base for medical universities. Currently, the industrial scale is constantly expanding.

Hanhai Gene is committed to significantly reducing the cost of genetic testing and providing high-quality genetic testing services. At present, the third-generation single-molecule direct sequencing technology has been successfully developed. This technology can greatly simplify the gene detection process, reduce sequencing costs and detection cycles by directly reading DNA and RNA information in blood or tissue.

Guangdong Wuzhou Pharmaceutical Co., Ltd. is a high-tech enterprise in Guangdong Province, a private technology enterprise in Guangdong Province, a national drug GMP certified enterprise, and an ISO9001:2000 quality management system certified enterprise; The company's "Tianqiao Brand" trademark is a well-known trademark in Guangdong Province;

Jiangxi Longlai Biopharmaceutical Co., Ltd. was founded in 2009 by Dr. Wu Shengwen, a renowned overseas expert who returned to China. It was completed in 2011 and merged with the American company Kairuist (Suzhou) Biochemical Co., Ltd. at the end of 2012. Currently, Dr. Wu Shengwen serves as the President of the merged new company and also serves as the Chairman and General Manager of Longlai Company. The company is led by internationally renowned investment bank Kaipeng Huaying from the United States, with other investors including Israel, Hong Kong, Japan, Suzhou, and Jiangxi Venture Capital. The company invested 100 million yuan in personnel in the early stage

Zhongke Hongji Biotechnology Co., Ltd. was established on April 14, 2010, with a registered capital of RMB 500 million. Its business scope is the research, development, and sales of biotechnology products. The company's construction adheres to the requirements of industrialization, agglomeration, and international development, adhering to the combination of expanding industrial scale and enhancing independent innovation capabilities, in order to accelerate the development of industries such as biopharmaceuticals, bio based chemicals, biomaterials, biological manufacturing, and biological environmental protection.